ZIM LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 107.9 INR | -2.75% |
|
+2.76% | -6.38% |
| 14/05 | Zim Laboratories' Consolidated Profit Climbs in Fiscal Q4; Shares Slide 5% | MT |
| 13/05 | ZIM Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
| Sales 2023 | 3.99B 47.8M | Sales 2024 | 3.68B 44.07M | Capitalization | 4.65B 55.8M |
|---|---|---|---|---|---|
| Net income 2023 | 244M 2.93M | Net income 2024 | 172M 2.06M | EV / Sales 2023 | 1.02 x |
| Net Debt 2023 | 557M 6.68M | Net Debt 2024 | 1.02B 12.22M | EV / Sales 2024 | 1.54 x |
| P/E ratio 2023 |
14.5
x | P/E ratio 2024 |
27
x | Employees | 556 |
| Yield 2023 * |
-
| Yield 2024 |
-
| Free-Float | 32.62% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.75% | ||
| 1 week | +2.76% | ||
| Current month | -2.75% | ||
| 1 month | +4.00% | ||
| 3 months | +11.31% | ||
| 6 months | -8.68% | ||
| Current year | -6.38% |
1 week
103.50
114.25
1 month
92.25114.25
Current year
89.90131.30
1 year
89.90151.75
3 years
36.37151.75
5 years
14.00151.75
10 years
14.00151.75
| Managers | Title | Age | Since |
|---|---|---|---|
Anwar Siraj Daud
CEO | Chief Executive Officer | - | 01/90/01 |
| Director of Finance/CFO | - | 01/19/01 | |
| Director of Finance/CFO | - | 01/91/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anwar Siraj Daud
CEO | Chief Executive Officer | - | 01/90/01 |
| Director of Finance/CFO | - | 01/91/01 | |
Prakash Sapkal
COO | Chief Operating Officer | - | 01/13/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/24/01 | 107.9 | -2.75% | 40 724 |
| 28/24/28 | 111 | +0.63% | 21,381 |
| 27/24/27 | 110.2 | +5.00% | 78,131 |
| 26/24/26 | 105 | 0.00% | 7,246 |
| 25/24/25 | 105 | 0.00% | 4,044 |
Delayed Quote Bombay S.E., July 01, 2024 at 03:30 pm IST
More quotes
ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. It is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.
Sector
Pharmaceuticals
Calendar
06/08/2024
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -6.38% | 64.85M | |
| +20.70% | 43.77B | |
| +30.16% | 22.83B | |
| +18.68% | 14.34B | |
| +54.86% | 12.96B | |
| -0.05% | 6.79B | |
| -11.72% | 6.41B | |
| -8.87% | 5.73B | |
| +14.65% | 5.69B | |
| +9.49% | 4.75B |
- Stock Market
- Equities
- ZIMLAB Stock
